Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.

PURPOSE To define the value of thymidylate synthase (TS), Ki-67, and p53 as prognostic markers in patients with stage II and III colon carcinoma. PATIENTS AND METHODS We retrospectively analyzed the prognostic value of TS, Ki-67, and p53 in 706 patients with Dukes' B (291 patients) or Dukes' C (415 patients) colon carcinoma who were treated with either surgery alone (275 patients) or surgery plus fluorouracil (FU)-leucovorin chemotherapy (431 patients) in National Surgical Adjuvant Breast and Bowel Project (NSABP) protocols C01-C04. All three markers were assayed using immunohistochemical techniques. RESULTS Using 5 years of follow-up data, our retrospective analysis demonstrated an association between TS intensity (relapse-free survival [RFS]: risk ratio [RR] = 1.46, P =.01; overall survival [OS]: RR = 1.54, P =.002), Ki-67 (RFS: RR = 0.76, P =.05; OS: RR = 0.62, P =.001), and p53 (RFS: RR = 1.49, P =.01; OS: RR = 1.21, P =.18) for RFS and OS. High TS intensity levels and positive p53 staining were associated with a worse outcome. Tumors containing a high percentage of Ki-67-positive cells enjoyed an improved outcome compared with those patients whose tumors contained relatively few positive cells. An interaction with treatment was not identified for any of the markers. CONCLUSION This retrospective investigation demonstrated that TS, Ki-67, and p53 staining each had significant prognostic value for patients with Dukes' B and C colon carcinoma. However, none of the markers could be used to clearly discern groups of individuals who would be predicted to derive greater or lesser benefit from the use of adjuvant chemotherapy.

[1]  D. Sargent,et al.  Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Blomgren,et al.  Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  B. Iacopetta,et al.  A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil , 2001, British Journal of Cancer.

[4]  P J Catalano,et al.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer. , 2001, The New England journal of medicine.

[5]  A. Monks,et al.  Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  F. Maley,et al.  Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  M. J. Fernández Aceñero,et al.  Prognostic influence of p53 nuclear overexpression in colorectal carcinoma , 2000, Diseases of the colon and rectum.

[8]  F. Bosman,et al.  p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. , 2000, European journal of cancer.

[9]  H. Blomgren,et al.  Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  A. Simpson,et al.  A proposal for the integration of immunohistochemical staining and DNA-based techniques for the determination of TP53 mutations in human carcinomas. , 2000, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[11]  G. Peters,et al.  Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  L. Påhlman,et al.  Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  A. Paradiso,et al.  Colorectal Clinical Experimental Oncology Laboratory and 2 , 2022 .

[14]  J. Hayashi,et al.  p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. , 1999, Cancer research.

[15]  A. Harris,et al.  Combined role of tumor angiogenesis, bcl‐2, and p53 expression in the prognosis of patients with colorectal carcinoma , 1999, Cancer.

[16]  V. Kosma,et al.  p21/WAF1 expression in human colorectal carcinoma: association with p53, transcription factor AP-2 and prognosis , 1999, British Journal of Cancer.

[17]  K. Kinzler,et al.  Disruption of p53 in human cancer cells alters the responses to therapeutic agents. , 1999, The Journal of clinical investigation.

[18]  M. Gregor,et al.  Influence of p53 status on prognosis in preoperatively irradiated rectal carcinoma , 1999, Cancer.

[19]  F. Maley,et al.  Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Allegra.  Antifolates: the next millennium. , 1999, Seminars in oncology.

[21]  A. Jackman,et al.  Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations. , 1999, European journal of cancer.

[22]  L. Påhlman,et al.  Prognostic value of p53 genetic changes in colorectal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  F. Cianchi,et al.  Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors. , 1999, Oncology research.

[24]  S. Cascinu,et al.  S‐phase fraction can predict event free survival in patients with pT2‐T3N0M0 colorectal carcinoma , 1998, Cancer.

[25]  S. Groshen,et al.  p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  P. Bunn,et al.  Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. , 1998, Cancer research.

[27]  M. Fukushima,et al.  A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance , 1998, Cancer.

[28]  S. Groshen,et al.  Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[30]  H. Lenz,et al.  Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. , 1997, Cancer letters.

[31]  R. Parsons,et al.  p53 alterations are associated with improved prognosis in distal colonic carcinomas. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  R M Schultz,et al.  LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. , 1997, Cancer research.

[33]  B. Karlan,et al.  DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. , 1996, Oncogene.

[34]  J. Eshleman,et al.  Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  L. Roncucci,et al.  Clinico-pathological correlation and prognostic significance of nuclear p53 protein in colorectal cancer. Colorectal Cancer Study Group of the University and Health Care District of Modena. , 1996, The Italian journal of gastroenterology.

[36]  R. Gafà,et al.  p53 expression in colorectal cancer: relation to tumor type, DNA ploidy pattern and short-term survival. , 1996, American journal of clinical pathology.

[37]  L. Påhlman,et al.  Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. , 1996, Anticancer research.

[38]  L. Holmberg,et al.  The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. , 1996, Journal of the National Cancer Institute.

[39]  Allegra Cj,et al.  Colorectal cancer biology: clinical implications. , 1995 .

[40]  P. Johnston,et al.  Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. , 1995, Cancer research.

[41]  H E Rockette,et al.  The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  K. Venkatesh,et al.  Comparison of double and single parameters in DNA analysis for staging and as a prognostic indicator in patients with colon and rectal carcinoma , 1994, Diseases of the colon and rectum.

[43]  C. Cordon-Cardo,et al.  p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  G. Viale,et al.  Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. , 1994, Journal of the National Cancer Institute.

[45]  G. Nakagawara,et al.  p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. , 1993, British Journal of Cancer.

[46]  I. Miyazaki,et al.  Expression of p53 protein in colorectal cancer and its relationship to short‐term prognosis , 1992, Cancer.

[47]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[48]  I. Judson,et al.  ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. , 1991, Cancer research.

[49]  H. Wieand,et al.  DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma , 1991, Cancer.